First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX)

PHARMACEUTICAL PREPARATIONS

Headquarters: United States
Market Cap: $1.3B

About First Tracks Biotherapeutics, Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

SentiSense also tracks daily options readings for First Tracks Biotherapeutics, Inc. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

First Tracks Biotherapeutics, Inc. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.